Prothena Corporation plc (NASDAQ:PRTA - Get Free Report)'s stock price passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $10.65 and traded as low as $6.31. Prothena shares last traded at $6.40, with a volume of 569,147 shares trading hands.
Wall Street Analysts Forecast Growth
Several equities analysts have commented on PRTA shares. Cantor Fitzgerald reissued a "neutral" rating on shares of Prothena in a report on Friday, June 20th. Chardan Capital dropped their target price on shares of Prothena from $40.00 to $18.00 and set a "buy" rating on the stock in a report on Tuesday, May 27th. Bank of America reiterated an "underperform" rating on shares of Prothena in a research note on Wednesday, May 28th. Piper Sandler dropped their price target on shares of Prothena from $110.00 to $81.00 and set an "overweight" rating for the company in a research note on Tuesday, May 27th. Finally, JMP Securities cut their target price on Prothena from $78.00 to $29.00 and set a "market outperform" rating on the stock in a research report on Tuesday, May 27th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $31.50.
View Our Latest Research Report on PRTA
Prothena Stock Performance
The company has a market cap of $334.80 million, a P/E ratio of -2.99 and a beta of 0.01. The business has a 50 day moving average price of $6.13 and a two-hundred day moving average price of $10.59.
Prothena (NASDAQ:PRTA - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The biotechnology company reported ($1.12) earnings per share for the quarter, missing the consensus estimate of ($0.92) by ($0.20). The company had revenue of $2.83 million for the quarter, compared to the consensus estimate of $8.18 million. Prothena had a negative return on equity of 21.61% and a negative net margin of 79.94%. The company's revenue was up 5500.0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.34) earnings per share. As a group, research analysts expect that Prothena Corporation plc will post -4.04 EPS for the current year.
Institutional Trading of Prothena
Several institutional investors and hedge funds have recently made changes to their positions in the company. Wellington Management Group LLP lifted its stake in shares of Prothena by 22.8% during the fourth quarter. Wellington Management Group LLP now owns 5,130,876 shares of the biotechnology company's stock worth $71,063,000 after purchasing an additional 952,088 shares in the last quarter. Boxer Capital Management LLC bought a new position in Prothena during the fourth quarter valued at about $9,556,000. Federated Hermes Inc. increased its stake in Prothena by 84.3% during the fourth quarter. Federated Hermes Inc. now owns 746,177 shares of the biotechnology company's stock valued at $10,335,000 after acquiring an additional 341,274 shares during the period. Finepoint Capital LP boosted its holdings in shares of Prothena by 51.6% in the 4th quarter. Finepoint Capital LP now owns 657,071 shares of the biotechnology company's stock worth $9,100,000 after acquiring an additional 223,600 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in Prothena by 93.7% during the 4th quarter. JPMorgan Chase & Co. now owns 387,350 shares of the biotechnology company's stock worth $5,365,000 after buying an additional 187,364 shares in the last quarter. 97.08% of the stock is owned by hedge funds and other institutional investors.
About Prothena
(
Get Free Report)
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
Further Reading
Before you consider Prothena, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prothena wasn't on the list.
While Prothena currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
